Faculty

Institution

Unit

Venue

Lance Heilbrun

Professor

Wayne State University

Affiliations

School of Medicine

Oncology

Lance Heilbrun is currently serving as an Oncology Professor at Wayne State University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Lance Heilbrun

Wayne State University

Professor

You can click a keyword to filter the displayed items

oncology cancer research pharmacology medicine urology cancer treatment health sciences prostate cancer cancer care clinical research clinical trials cancer biology pharmacotherapy anti-cancer agents medicinal research phase ii trial cancer management genitourinary cancers tumor biology cancer risk cancer imaging colorectal cancer phase ii study nutrition clinical nutrition thoracic oncology human nutrition clinical epidemiology nutritional sciences tumor targeting surgical oncology public health nutrition medical nutrition cancer genomics dietary health pancreatic cancer clinical investigation respiratory medicine experimental medicine interventional radiology oral cancer drug trials radiation therapy bone research gynecologic oncology cellular therapy clinical evidence cancer genetics cancer disparities free radical biology leukemia therapeutic efficacy positron emission tomography prospective study clinical medicine gastrointestinal oncology epidemiology of cancer neck oncology advanced colorectal cancer stem cell transplantation cancer prevention medical genetics advanced pancreatic cancer african american men transplantation medicine nutrient physiology bone mineral content percutaneous cryoablation breast health study metastatic colorectal cancer autopsy study specific sites advanced pancreatic carcinoma pilot trial flavone acetic acid risk factors survival analysis statistical methods kidney cancer biostatistics

Notable Scholarly Works

Notable Federal Grants

Collaborators

Data From Race-Related Differences in Sipuleucel-T Response Among Men With Metastatic Castrate–Resistant Prostate Cancer. (2024)

Elisabeth I. HeathArchana ThakurWei ChenClara HwangChanning J. PallerFrank C. CackowskiJulie L. BoernerLance HeilbrunMelanie P. SmithDana L. SchalkAmy SchienschangSarah A. WhitakerAmanda PolendDaryn SmithUlka N. VaishampayanBrenda DickowLawrence G. Lum

neurologyrace-related differencessipuleucel-t responsecancer researchurologybiostatisticscross-sectional studiesprostate cancercancer disparities

Phase II Trial of Multi-Kinase Inhibitor Esk981 in Patients With Metastatic Castration-Resistant Prostate Cancer. Investigational New Drugs (2024)

Elisabeth I HeathWei ChenLance HeilbrunJae E ChoiKimberlee DobsonMelanie SmithTomasz MajUlka VaishampayanIlona KryczekWeiping ZouArul M ChinnaiyanYuanyuan Qiao

neurologypharmacologycancer researchurologyclinical trialsphase ii trialoncologyclinical researchcancer treatmentprostate cancerexperimental medicinedrug trials

Elisabeth I. HeathArchana ThakurWei ChenClara HwangChanning J. PallerFrank C CackowskiJulie L. BoernerLance HeilbrunMelanie P. SmithDana L. SchalkAmy SchienschangSarah A. WhitakerAmanda PolendDaryn SmithUlka N. VaishampayanBrenda DickowLawrence G. Lum

race-related differencessipuleucel-t responsecancer researchurologyoncologycancer biologyprostate cancerhealth sciencescancer disparities

Supplementary Figure S3A From Race-Related Differences in Sipuleucel-T Response Among Men With Metastatic Castrate–Resistant Prostate Cancer. (2024)

race-related differencessipuleucel-t responseurologyoncologyprostate cancer

Data From Phase 0 Trial of Azd1775 in First-Recurrence Glioblastoma Patients. (2023)

Nader SanaiJing LiJulie BoernerKarri StarkJianmei WuSeongho KimAlanna DerogatisShwetal MehtaHarshil D. DhruvLance K. HeilbrunMichael E. BerensPatricia M. LoRusso

neurologyrandomized controlled trialsradiation oncologyclinical trialsbiostatisticsoncologyneuro-oncology

Data From Transcriptional Regulation of Cxcr4 in Prostate Cancer: Significance of Tmprss2-Erg Fusions. (2023)

Rajareddy SingareddyLouie SemaanM. Katie Conley-LaCombJason St. JohnKatelyn PowellMatthew IyerDaryn SmithLance K. HeilbrunDongping ShiWael SakrMichael L. CherSreenivasa R. Chinni

gene expressionpharmacologytranscription regulationtranscriptional regulationcell signalingtumor biologygeneticstranscription factorsmolecular cancermolecular regulationgene functioncancer genomicsmolecular biologyoncogenesprostate cancergene regulation

Phase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible Patients. International Journal of Radiation Oncology*Biology*Physics (2023)

Ulka N. VaishampayanLance HeilbrunNitin VaishampayanFelicity W.K. HarperDongping ShiDaryn SmithKelly GreenKhurshid GuruQiang LiMichael KuettelGurkamal ChattaJordan MaierBrenda DickowTanina Foster MooreSaby George

bladder cancerradiation oncologyphase ii trialchemotherapy-ineligible patientsbreast cancermuscle-invasive bladder cancerradiation therapy

Supplementary Data From Biomarkers and Bone Imaging Dynamics Associated With Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. (2023)

Ulka N. VaishampayanIzabela PodgorskiLance K. HeilbrunJawana M. Lawhorn-CrewsKimberlee C. DobsonJulie BoernerKarri StarkDaryn W. SmithElisabeth I. HeathJoseph A. FontanaAnthony F. Shields

pharmacologyradiologysupplementary dataoral cabozantinib therapyclinical outcomescancer researchurologycancer genomicsgenitourinary cancersclinical trialscancer imagingoncologyclinical researchcancer treatmentprostate cancer

Supplementary Figure 1 From Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(Adp-Ribose) Polymerase (Parp) Inhibitor Veliparib (Abt-888) in Combination With Irinotecan in Patients With Advanced Solid Tumors. (2023)

Patricia M. LoRussoJing LiAngelika BurgerLance K. HeilbrunEdward A. SausvilleScott A. BoernerDaryn SmithMary Jo PilatJie ZhangSara M. TolaneyJames M. ClearyAlice P. ChenLawrence RubinsteinJulie L. BoernerAdam BowditchDongpo CaiTracy BellAndrew WolanskiAllison M. MarreroYiping ZhangJiuping JiKatherine Ferry-GalowRobert J. KindersRalph E. ParchmentGeoffrey I. Shapiro

medicinal chemistrypharmacodynamic studydrug safetyenzyme inhibitionpharmacologyradiation oncologypharmacotherapyanti-cancer agentsdrug discoveryoncologyinhibitor veliparibcancer treatmenttherapeutic efficacydrug development

Supplementary Figure Legends From Transcriptional Regulation of Cxcr4 in Prostate Cancer: Significance of Tmprss2-Erg Fusions. (2023)

Rajareddy SingareddyLouie SemaanM. Katie Conley-LaCombJason St. JohnKatelyn PowellMatthew IyerDaryn SmithLance K. HeilbrunDongping ShiWael SakrMichael L. CherSreenivasa R. Chinni

leukemiapharmacologytranscriptional regulationfunctional genomicsgene regulatory networkstranscription (biology)cell signalinggeneticsmolecular cancercancer genomicsmolecular regulationgene functionmolecular biologyoncogenesprostate cancermembrane biologygene regulation

1
2
3
4
5
28
10 / page

Lance Heilbrun

Professor

Wayne State University

Affiliations

School of Medicine

Oncology

Lance Heilbrun is currently serving as an Oncology Professor at Wayne State University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Lance Heilbrun

Wayne State University

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Data From Race-Related Differences in Sipuleucel-T Response Among Men With Metastatic Castrate–Resistant Prostate Cancer. (2024)

neurologyrace-related differencessipuleucel-t responsecancer researchurologybiostatisticscross-sectional studiesprostate cancercancer disparities

Phase II Trial of Multi-Kinase Inhibitor Esk981 in Patients With Metastatic Castration-Resistant Prostate Cancer. Investigational New Drugs (2024)

Elisabeth I HeathWei ChenLance HeilbrunJae E ChoiKimberlee DobsonMelanie SmithTomasz MajUlka VaishampayanIlona KryczekWeiping ZouArul M ChinnaiyanYuanyuan Qiao

neurologypharmacologycancer researchurologyclinical trialsphase ii trialoncologyclinical researchcancer treatmentprostate cancerexperimental medicinedrug trials

race-related differencessipuleucel-t responsecancer researchurologyoncologycancer biologyprostate cancerhealth sciencescancer disparities

Supplementary Figure S3A From Race-Related Differences in Sipuleucel-T Response Among Men With Metastatic Castrate–Resistant Prostate Cancer. (2024)

race-related differencessipuleucel-t responseurologyoncologyprostate cancer

Data From Phase 0 Trial of Azd1775 in First-Recurrence Glioblastoma Patients. (2023)

Nader SanaiJing LiJulie BoernerKarri StarkJianmei WuSeongho KimAlanna DerogatisShwetal MehtaHarshil D. DhruvLance K. HeilbrunMichael E. BerensPatricia M. LoRusso

neurologyrandomized controlled trialsradiation oncologyclinical trialsbiostatisticsoncologyneuro-oncology

Data From Transcriptional Regulation of Cxcr4 in Prostate Cancer: Significance of Tmprss2-Erg Fusions. (2023)

Rajareddy SingareddyLouie SemaanM. Katie Conley-LaCombJason St. JohnKatelyn PowellMatthew IyerDaryn SmithLance K. HeilbrunDongping ShiWael SakrMichael L. CherSreenivasa R. Chinni

bladder cancerradiation oncologyphase ii trialchemotherapy-ineligible patientsbreast cancermuscle-invasive bladder cancerradiation therapy

Supplementary Data From Biomarkers and Bone Imaging Dynamics Associated With Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. (2023)

Ulka N. VaishampayanIzabela PodgorskiLance K. HeilbrunJawana M. Lawhorn-CrewsKimberlee C. DobsonJulie BoernerKarri StarkDaryn W. SmithElisabeth I. HeathJoseph A. FontanaAnthony F. Shields

Supplementary Figure Legends From Transcriptional Regulation of Cxcr4 in Prostate Cancer: Significance of Tmprss2-Erg Fusions. (2023)

Rajareddy SingareddyLouie SemaanM. Katie Conley-LaCombJason St. JohnKatelyn PowellMatthew IyerDaryn SmithLance K. HeilbrunDongping ShiWael SakrMichael L. CherSreenivasa R. Chinni

1
2
3
4
5
28
10 / page

Similar Faculty Members

Elisabeth Heath

Institution

Wayne State University

translational research

prostate cancer research

Afshin Dowlati

Institution

Case Western Reserve University

cancer letter

bronchial neoplasm

Steven K Clinton

Institution

Ohio State University

health sciences

oncology

Heather Wakelee

Institution

Stanford University

radiation oncology

mesothelioma

Frank L. Meyskens

Institution

University of California, Irvine

oncology

cancer research

Peter G Shields

Institution

Ohio State University

applied artificial intelligence

multidisciplinary ai

Kenneth Boucher

Institution

University of Utah

cancer letter

biomedical data science

Donna Niedzwiecki

Institution

Duke University

gi cancer

radiation oncology

Quynh-Thu Le

Institution

Stanford University

radiation oncology

oral pathology

Seongho Kim

Institution

Wayne State University

data analysis

personalized medicine

Similar Faculty Members

Elisabeth Heath

Institution

Wayne State University

translational research

prostate cancer research

Afshin Dowlati

Institution

Case Western Reserve University

cancer letter

bronchial neoplasm

Steven K Clinton

Institution

Ohio State University

health sciences

oncology

Heather Wakelee

Institution

Stanford University

radiation oncology

mesothelioma

Frank L. Meyskens

Institution

University of California, Irvine

oncology

cancer research

Peter G Shields

Institution

Ohio State University

applied artificial intelligence

multidisciplinary ai

Kenneth Boucher

Institution

University of Utah

cancer letter

biomedical data science

Donna Niedzwiecki

Institution

Duke University

gi cancer

radiation oncology

Quynh-Thu Le

Institution

Stanford University

radiation oncology

oral pathology

Seongho Kim

Institution

Wayne State University

data analysis

personalized medicine